Hepatic encephalopathy: from pathophysiology to therapeutic management

被引:66
作者
Bismuth, Michael
Funakoshi, Natalie
Cadranel, Jean-Francois [2 ]
Blanc, Pierre [1 ]
机构
[1] CHU Montpellier, Hop St Eloi, F-34295 Montpellier 5, France
[2] CHG Laennec, Serv Hepatogastroenterol & Nutr, Creil, France
关键词
cirrhosis; hepatic encephalopathy; portal hypertension portosystemic shunt; INTRAHEPATIC PORTOSYSTEMIC SHUNT; ACUTE LIVER-FAILURE; PORTAL-SYSTEMIC ENCEPHALOPATHY; AUTOPSIED BRAIN-TISSUE; HELICOBACTER-PYLORI INFECTION; ACUTE AMMONIA INTOXICATION; SOLUBLE GUANYLATE-CYCLASE; GAMMA-AMINOBUTYRIC-ACID; ORNITHINE-L-ASPARTATE; DOUBLE-BLIND;
D O I
10.1097/MEG.0b013e3283417567
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatic encephalopathy is a complex and potentially reversible neuropsychiatric syndrome complicating acute or chronic liver disease. Clinical manifestations are multiple and varied, ranging from minimal neurological changes to coma. Ammonia is the main toxic substance involved in the pathogenesis of hepatic encephalopathy, although other mechanisms, such as modifications of the blood-brain barrier, disruptions in neurotransmission and abnormalities in GABAergic and benzodiazepine pathways may also play a role. The identification and treatment of precipitating factors is crucial in the management of patients with hepatic encephalopathy. Current treatments are based on reducing intestinal ammonia load by agents such as antibiotics or disaccharides, although their efficacy is yet to be clearly established. Eur J Gastroenterol Hepatol 23:8-22 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:8 / 22
页数:15
相关论文
共 144 条
  • [1] The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy
    Ahboucha, Samir
    Butterworth, Roger F.
    [J]. METABOLIC BRAIN DISEASE, 2007, 22 (3-4) : 291 - 308
  • [2] Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma
    Ahboucha, Samir
    Pomier-Layrargues, Gilles
    Mamer, Orval
    Butterworth, Roger F.
    [J]. NEUROCHEMISTRY INTERNATIONAL, 2006, 49 (04) : 372 - 378
  • [3] Als-Nielsen B, 2004, Cochrane Database Syst Rev, DOI 10.1002/14651858.CD003044.pub2
  • [4] ALSNIELSEN B, 2004, COCHRANE DB SYST REV, V2
  • [5] Hyponatremia in cirrhosis:: Results of a patient population survey
    Angeli, Paolo
    Wong, Florence
    Watson, Hugh
    Gines, Pere
    [J]. HEPATOLOGY, 2006, 44 (06) : 1535 - 1542
  • [6] [Anonymous], COCHRANE DATABASE SY
  • [7] Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: An Italian multicenter double-blind, placebo-controlled, cross-over study
    Barbaro, G
    Di Lorenzo, G
    Soldini, M
    Giancaspro, G
    Bellomo, G
    Belloni, G
    Grisorio, B
    Annese, M
    Bacca, D
    Francavilla, R
    Barbarini, G
    [J]. HEPATOLOGY, 1998, 28 (02) : 374 - 378
  • [8] ELEVATED BRAIN CONCENTRATIONS OF 1,4-BENZODIAZEPINES IN FULMINANT HEPATIC-FAILURE
    BASILE, AS
    HUGHES, RD
    HARRISON, PM
    MURATA, Y
    PANNELL, L
    JONES, EA
    WILLIAMS, R
    SKOLNICK, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (07) : 473 - 478
  • [9] BASILE AS, 1988, J NEUROSCI, V8, P2414
  • [10] Review article: the current pharmacological therapies for hepatic encephalopathy
    Bass, N. M.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 : 23 - 31